OHRP Retreats from Providing Public Info re: Compliance Activities

August 26, 2002 OHRP Retreats from Providing Public Info re: Compliance Activities FYI A newly posted announcement by the Office of Human Research Protection (OHRP), dated July 15, rescinds the agency’s announced policy of making public the content of its letters of . . . Continue reading →

HMO physician applauds Spitzer’s focus on information bias / NYT blind spot

HMO physician applauds Spitzer’s focus on information bias / NYT blind spot Sun, 20 Jun 2004 The affirmation by a Kaiser Permanente physician, Dr. Kate Scannell, that NYS Attorney General, Eliot Spitzer, deserves applause for his “bold and courageous” lawsuit, is an . . . Continue reading →

FDA Forced Wyeth to REMOVE Suicide Warning from Effexor Label

FDA Forced Wyeth to REMOVE Suicide Warning from Effexor Label Wed, 8 Sep 2004 The Wall Street Journal reports that FDA officials forced Wyeth to remove the label warning stating: “In pediatric clinical trials, there were increased reports of hostility and, especially . . . Continue reading →

Lilly duloxetine drug trial–19 Quit after a suicide – Philadelphia Inquirer

Lilly duloxetine drug trial–19 Quit after a suicide – Philadelphia Inquirer Fri, 13 Feb 2004 19-year old Teri Johnson’s suicide occurred one week after an FDA advisory committee had urged the FDA to issue warnings about prescribing antidepressant drugs for children under . . . Continue reading →

Congress & the White House must remedy a prescription for danger – LA Times / CBS News

Congress & the White House must remedy a prescription for danger – LA Times / CBS News Thu, 1 Apr 2004 For those who missed the CBS evening News broadcast (Tues March 30) about FDA’s suppression of evidence, a video of that . . . Continue reading →

Concealed Drug Trial Results Mislead Doctors & Put Children’s Lives at Risk – NYT

Concealed Drug Trial Results Mislead Doctors & Put Children’s Lives at Risk – NYT Thu, 22 Jul 2004 The inordinate influence that drug companies wield on government healthcare regulatory policies–through campaign contributions to elected officials and lucrative job offers to public officials–has . . . Continue reading →

Fast growing business: Unethical clinical trials in India – Asia Times

Fast growing business: Unethical clinical trials in India – Asia Times Tue, 27 Jul 2004 Asia Times reports: “India increasingly emerges as a preferred destination for outsourcing clinical trials – testing of new drugs on humans – the country may also be . . . Continue reading →

Lilly Withdraws Duloxetine Application from FDA

Lilly Withdraws Duloxetine Application from FDA Fri, 28 Jan 2005 Eli Lilly and Boeringer Ingelheim have jointly announced that they have recinded their U.S. FDA Application for Duloxetine for Treatment of Stress Urinary Incontinence. http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=154081&print=yes Withdrawal of an application from FDA approval . . . Continue reading →